158 related articles for article (PubMed ID: 33392508)
1. Tumor edge-to-core transition promotes malignancy in primary-to-recurrent glioblastoma progression in a PLAGL1/CD109-mediated mechanism.
Li C; Cho HJ; Yamashita D; Abdelrashid M; Chen Q; Bastola S; Chagoya G; Elsayed GA; Komarova S; Ozaki S; Ohtsuka Y; Kunieda T; Kornblum HI; Kondo T; Nam DH; Nakano I
Neurooncol Adv; 2020; 2(1):vdaa163. PubMed ID: 33392508
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation.
Minata M; Audia A; Shi J; Lu S; Bernstock J; Pavlyukov MS; Das A; Kim SH; Shin YJ; Lee Y; Koo H; Snigdha K; Waghmare I; Guo X; Mohyeldin A; Gallego-Perez D; Wang J; Chen D; Cheng P; Mukheef F; Contreras M; Reyes JF; Vaillant B; Sulman EP; Cheng SY; Markert JM; Tannous BA; Lu X; Kango-Singh M; Lee LJ; Nam DH; Nakano I; Bhat KP
Cell Rep; 2019 Feb; 26(7):1893-1905.e7. PubMed ID: 30759398
[TBL] [Abstract][Full Text] [Related]
3. Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy.
Bastola S; Pavlyukov MS; Yamashita D; Ghosh S; Cho H; Kagaya N; Zhang Z; Minata M; Lee Y; Sadahiro H; Yamaguchi S; Komarova S; Yang E; Markert J; Nabors LB; Bhat K; Lee J; Chen Q; Crossman DK; Shin-Ya K; Nam DH; Nakano I
Nat Commun; 2020 Sep; 11(1):4660. PubMed ID: 32938908
[TBL] [Abstract][Full Text] [Related]
4. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
Cuppini L; Calleri A; Bruzzone MG; Prodi E; Anghileri E; Pellegatta S; Mancuso P; Porrati P; Di Stefano AL; Ceroni M; Bertolini F; Finocchiaro G; Eoli M
PLoS One; 2013; 8(9):e74345. PubMed ID: 24069296
[TBL] [Abstract][Full Text] [Related]
6. CDC20 maintains tumor initiating cells.
Xie Q; Wu Q; Mack SC; Yang K; Kim L; Hubert CG; Flavahan WA; Chu C; Bao S; Rich JN
Oncotarget; 2015 May; 6(15):13241-54. PubMed ID: 25938542
[TBL] [Abstract][Full Text] [Related]
7. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
8. CD109 identified in circulating proteomics mitigates postoperative recurrence in chronic rhinosinusitis with nasal polyps by suppressing TGF-β1-induced epithelial-mesenchymal transition.
Gao R; Chen Y; Liu H; Ye M; Chu L; Wang T
Int Immunopharmacol; 2024 Mar; 130():111793. PubMed ID: 38442581
[TBL] [Abstract][Full Text] [Related]
9. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
[TBL] [Abstract][Full Text] [Related]
10. Tumor-initiating cell frequency is relevant for glioblastoma aggressiveness.
Richichi C; Osti D; Del Bene M; Fornasari L; Patanè M; Pollo B; DiMeco F; Pelicci G
Oncotarget; 2016 Nov; 7(44):71491-71503. PubMed ID: 27582543
[TBL] [Abstract][Full Text] [Related]
11. CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Kim JS; Shin MJ; Lee SY; Kim DK; Choi KU; Suh DS; Kim D; Kim JH
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373457
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
13. CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer.
Adachi K; Sakurai Y; Ichinoe M; Tadehara M; Tamaki A; Kesen Y; Kato T; Mii S; Enomoto A; Takahashi M; Koizumi W; Murakumo Y
Virchows Arch; 2022 Apr; 480(4):819-829. PubMed ID: 34762199
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinoma.
Ye BG; Sun HC; Zhu XD; Chai ZT; Zhang YY; Ao JY; Cai H; Ma DN; Wang CH; Qin CD; Gao DM; Tang ZY
Oncotarget; 2016 May; 7(20):29333-45. PubMed ID: 27121053
[TBL] [Abstract][Full Text] [Related]
15. Revealing the glioma cancer stem cell interactome, one niche at a time.
Silver DJ; Lathia JD
J Pathol; 2018 Mar; 244(3):260-264. PubMed ID: 29282720
[TBL] [Abstract][Full Text] [Related]
16. Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors.
Knudsen AM; Halle B; Cédile O; Burton M; Baun C; Thisgaard H; Anand A; Hubert C; Thomassen M; Michaelsen SR; Olsen BB; Dahlrot RH; Bjerkvig R; Lathia JD; Kristensen BW
Neuro Oncol; 2022 Jul; 24(7):1074-1087. PubMed ID: 34964899
[TBL] [Abstract][Full Text] [Related]
17. CD109 attenuates TGF-β1 signaling and enhances EGF signaling in SK-MG-1 human glioblastoma cells.
Zhang JM; Murakumo Y; Hagiwara S; Jiang P; Mii S; Kalyoncu E; Saito S; Suzuki C; Sakurai Y; Numata Y; Yamamoto T; Takahashi M
Biochem Biophys Res Commun; 2015 Apr; 459(2):252-258. PubMed ID: 25724945
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN
Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3.
Wang CA; Harrell JC; Iwanaga R; Jedlicka P; Ford HL
Breast Cancer Res; 2014 Oct; 16(5):462. PubMed ID: 25358638
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis.
Yang YP; Chang YL; Huang PI; Chiou GY; Tseng LM; Chiou SH; Chen MH; Chen MT; Shih YH; Chang CH; Hsu CC; Ma HI; Wang CT; Tsai LL; Yu CC; Chang CJ
J Cell Physiol; 2012 Mar; 227(3):976-93. PubMed ID: 21503893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
